Last reviewed · How we verify

bevacizumab, erlotinib — Competitive Intelligence Brief

bevacizumab, erlotinib (bevacizumab, erlotinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor, EGFR inhibitor. Area: Oncology.

phase 3 VEGF inhibitor, EGFR inhibitor VEGF-A, EGFR Oncology Biologic Live · refreshed every 30 min

Target snapshot

bevacizumab, erlotinib (bevacizumab, erlotinib) — Swiss Cancer Institute. Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while erlotinib is a small molecule tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
bevacizumab, erlotinib TARGET bevacizumab, erlotinib Swiss Cancer Institute phase 3 VEGF inhibitor, EGFR inhibitor VEGF-A, EGFR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor, EGFR inhibitor class)

  1. Swiss Cancer Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bevacizumab, erlotinib — Competitive Intelligence Brief. https://druglandscape.com/ci/bevacizumab-erlotinib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: